Jump to main navigation Skip to Content

DFG Logo: back to Homepage Deutsche Forschungsgemeinschaft

DFG Contacts

Stand: December 12, 2018

Dr. Stefan Thiel

Programme Director
Life Sciences 3: Medicine

E-Mail: stefan.thiel@dfg.de
Telephone: +49 (228) 885-2977
Telefax: +49 (228) 885-713320
Kennedyallee 40
53175 Bonn


Tasks and Responsibilities

General Responsibilities

Clinical Trials
Coordination - Cancer Research

Support of DFG Statutory Bodies

Hinterzarten Circle on Cancer Research

Scientific Areas of Responsibility

205-14 Medicine
205-31 Medicine

Scientific Areas of Responsibility (Deputy Contact)

205-06 Medicine
205-21 Medicine
205-25 Medicine

Coordinated Programmes (procedural matters)

Clinical Research Units

262 Der Tumormetabolismus als Modulator der Immunantwort und Tumorprogression
286 Exploiting defects in the DNA damage response for the treatment of chronic lymphocytic leukemia

Priority Programmes

1230 Mechanisms of gene vector entry and persistence
1463 Epigenetic regulation of normal hematopoiesis and its dysregulation in myeloid neoplasia
2084 µBONE: Colonization and interaction of tumor cells within the bone microenvironment

Research Units

1586 SKELMET- Mesenchymal and osteogenic signaling pathways in malignant bone diseases
2033 The Hematopoietic Niches
2314 Targeting therapeutic windows in essential cellular processes for tumor therapy
2674 Aging-related epigenetic remodeling in acute myeloid leukemia

Coordinated Programmes (scientific matters)

CRC/Transregios

221 Modulation of graft-versus-host and graft-versus leukemia immune responses after allogeneic stem cell transplantation
240 Platelets – Molecular, cellular and systemic functions in health and disease

Collaborative Research Centres

850 Control of Cell Motility in Morphogenesis, Cancer Invasion and Metastasis
873 Maintenance and Differentiation of Stem Cells in Development and Disease
1074 Experimental Models and Clinical Translation in Leukemia
1243 Genetic and Epigenetic Evolution of Hematopoietic Neoplasms

Research Training Groups

2375 Tumor-Targeted Drug Delivery